Graft - versus - host disease (GVHD) is the major complication after
allogeneic bone marrow transplantation.
Donor - type CD4 (+) CD25 (+) regulatory T cells suppress lethal acute graft - versus - host disease after
allogeneic bone marrow transplantation.
The only documented long - term complete remissions reported in multiple myeloma patients have occurred with
allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.
Not exact matches
Collaboration with Hematology and
Bone Marrow Transplantation Unit research group in molecular diagnostics applied to the management of patients undergoing
allogeneic SCT, especially for the detection of minimal residual disease and early relapse.
Board - certified in internal medicine and medical oncology, Dr. Collins has 25 years of experience in
bone marrow transplantation and has participated in some 2,500 autologous and
allogeneic transplants.
In the future, outpatient blood and
bone marrow stem cell
transplantation will be offered to a broader group of patients with other blood disorders and for
allogeneic transplants (transplant from non-twin donor stem cells).
Allogeneic stem cell
transplantation to leukaemic patients, in which the patient's own diseased
bone marrow is replaced by healthy donor material, is one of the best - established and most effective immunological therapies.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European
Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with
allogeneic stem cell
transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.